Stocks · News reference

Nyxoah shares are trading higher after the company announced that the ACCCESS U.S. pivotal study met its co-primary efficacy endpoint.

Sep 2, 2026, 8:37 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 2, 2026, 8:07 PMBenzinga Newsdesk
Nyxoah's ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse PatientsReports an Apnea-Hypopnea Index (AHI) responder rate of 77.2% on a Full Analysis Set basis
NYXH
BenzingaAug 17, 2026, 11:15 AMBenzinga Newsdesk
Cantor Fitzgerald Maintains Overweight on Nyxoah, Lowers Price Target to $6
Cantor Fitzgerald analyst Sarah James maintains Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $11 to $6.
NYXH
BenzingaAug 6, 2026, 4:43 PMBenzinga Newsdesk
Piper Sandler Reiterates Overweight on Nyxoah, Lowers Price Target to $6
Piper Sandler analyst Adam Maeder reiterates Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $7 to $6.
NYXH